VBI VACCINES INC(NASDAQ:VBIV) stock News

VBIV Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: InvestorPlace - Mentions: CYRX DZSI EBS EVAV ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

a year ago - By: Benzinga - Mentions: XAIR ZCMD EVO LUMN ...

Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

a year ago - By: Benzinga - Mentions: RGC ELEV JMIA LUMN ...

Dow Jumps Over 300 Points; US Trade Gap Narrows In June

a year ago - By: InvestorPlace

Why Is VBI Vaccines (VBIV) Stock Up 62% Today?

a year ago - By: BusinessInsider

VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024

a year ago - By: InvestorPlace - Mentions: AGRI ATPC CHGG CRVO ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Provides an Update on its Restructuring Proceedings

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Announces Results of Annual General Meeting

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

a year ago - By: InvestorPlace

VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Reports First Quarter 2024 Financial Results

a year ago - By: InvestorPlace

VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Reports Full Year 2023 Financial Results

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

a year ago - By: InvestorPlace - Mentions: MDIA FAAS HUBC GRIN ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform

a year ago - By: Seeking Alpha

VBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences

a year ago - By: VBI Vaccines Inc.

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

a year ago - By: Brii Biosciences Limited

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Reports Third Quarter 2023 Financial Results

2 years ago - By: VBI Vaccines Inc.

VBI VACCINES INC (VBIV) Stock News

VBIV Latest News, Press Relases and Analysis

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Dow Jumps Over 300 Points; US Trade Gap Narrows In June

Why Is VBI Vaccines (VBIV) Stock Up 62% Today?

VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

VBI Vaccines Provides an Update on its Restructuring Proceedings

VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

VBI Vaccines Announces Results of Annual General Meeting

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024

VBI Vaccines Reports First Quarter 2024 Financial Results

VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023

VBI Vaccines Reports Full Year 2023 Financial Results

VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform

VBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting

VBI Vaccines Reports Third Quarter 2023 Financial Results

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program